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Abstract 
BACKGROUND: Bacterial infections are involved in more than a half of the exacerbations of chronic obstructive 
pulmonary disease (COPD).  
AIM: To evaluate the efficacy and safety of moxifloxacin in the outpatient treatment of moderate exacerbations of 
bacterial origin in the COPD patients. 
METHODS: We performed a prospective, observational study including 64 COPD patients with moderate 
exacerbation of bacterial origin empirically treated with moxifloxacin. In 31 of them, moxifloxacin was used as an 
initial antibiotic (Group 1), whereas in 33 of them moxifloxacin was used after treatment failure with another 
antibiotic (Group 2). All patients have treated 7 days with moxifloxacin 400 mg once daily per os, and they were 
followed up for 20 days, with an intermediate visit at 3, 5 and 7 days at which the duration of symptoms and the 
side effects of the drug were evaluated. 
RESULTS: We registered high clinical success rate, i.e. the complete resolution of the symptoms or their return to 
the baseline severity, similar in both groups (84.3% in all study subjects, 83.9% in the Group 1 and 84.8% in the 
Group 2). The mean time to complete resolution of the cardinal symptoms or their return to the baseline severity 
was 5.2 ± 1.1 days. Also, the mean time to complete resolution of the certain cardinal symptoms (increased 
dyspnea, increased sputum volume and increased sputum purulence) or their return to the baseline severity is 
given 4.9, 4.7 and 4.2 days, respectively. The incidence of adverse effects during the treatment with moxifloxacin 
in all study subjects was 10.9%, 9.6% in Group 1 and 12.1% in Group 2. There was no serious adverse effect that 
required discontinuation of the treatment. Relapse during a 20 days follow-up period was registered in 7.4% of the 
all study subjects with complete resolution of the cardinal symptoms or their return to the baseline severity, i.e. in 
two patients from both Group 1 and Group 2 (7.6% and 7.1%, respectively).  
CONCLUSION: Our findings suggest high efficacy and good tolerability of moxifloxacin in the treatment of 
moderate COPD exacerbations of bacterial origin. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Exacerbations of chronic obstructive 
pulmonary disease (COPD) are important events in 
the course of the disease because they greatly 
contribute to the rates of hospitalisation and 
readmission, disease progression and mortality. 
According to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 2017 Report, 
COPD exacerbations are defined as an acute 
worsening of respiratory symptoms that result in 
additional therapy [1]. Respiratory infections, 
environmental and occupational exposures, 
discontinuation of the regular treatment, and 
worsening of the comorbid conditions are considered 
as causes of exacerbations, but in up 20% of the 
cases, the cause of exacerbation remains unknown 
[2] [3]. 
The goals of treatment for COPD 
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exacerbations are to minimise the negative impact of 
the current exacerbation and prevent the development 
of subsequent events. According to their severity and 
management, COPD exacerbations are classified as 
mild (treated with short-acting bronchodilators), 
moderate (treated with short-acting bronchodilators 
plus antibiotics and oral corticosteroids) and severe 
(requiring hospitalisation or visit to the emergency 
room). Depending on the severity of an exacerbation 
and/or the severity of the underlying disease, an 
exacerbation can be managed in an outpatient or 
inpatient setting. More than 80% of COPD 
exacerbations are managed in an outpatient setting 
with pharmacological treatment including short-acting 
bronchodilators, antibiotics and/or corticosteroids [1].  
Respiratory infections account for up to 80% 
of exacerbations, of which bacterial infections are 
involved in around 50-70%. The predominant bacteria 
recovered from the lower airways in patients with 
chronic bronchitis (CB) and COPD exacerbations are 
Streptococcus pneumoniae, Haemophilus influenza, 
and Moraxella catarrhalis. Atypical bacteria, e. g. 
Mycoplasma pneumoniae and Chlamydia 
pneumoniae are implicated in up to 10% of 
exacerbations [4] [5]. The criteria of Anthonisen i.e. 
increased dyspnea, sputum volume and purulence, 
are still the most important classification system to 
identify patients likely to be infected with bacterial 
pathogens based on the presentation of clinical 
symptoms [6] [7] [8]. Current treatment guidelines 
recommend antibiotic therapy in patients with 
Anthonisen criteria of type I (all cardinal symptoms) or 
II (two cardinal symptoms) if increased purulence of 
sputum is one of the two symptoms and in patients 
who require mechanical ventilation (invasive or non-
invasive). The choice of the antibiotic is based on the 
local bacterial resistance pattern. Usually, initial 
empirical treatment is an aminopenicillin with 
clavulanic acid, macrolide, or doxycycline. The 
recommended length of antibiotic therapy is 5-7 days. 
Resolution of exacerbation is considered as a 
complete resolution of cardinal symptoms or their 
return to the baseline severity [1] [9] [10].  
Moxifloxacin is a fourth generation 
fluoroquinolone with a broad spectrum of activity 
against a wide range of the microorganisms, including 
Gram-positive and Gram-negative bacteria, atypical 
pathogens, and anaerobic bacteria, i.e. against nearly 
all treatable bacteria associated with COPD 
exacerbations, including Streptococcus pneumoniae, 
Haemophilus influenza, Moraxella catarrhalis, most 
Staphylococcus aureus, Mycoplasma pneumoniae, 
Chlamydia pneumoniae, etc. Also, moxifloxacin may 
be regarded as the most excellent tissue ability. 
Common side effects associated with the use of 
moxifloxacin are abdominal discomfort, nausea, 
vomiting, diarrhoea, headache, dizziness, blurred 
vision, anxiety, and skin itching. Serious side effects 
of moxifloxacin which occur rarely include severe 
diarrhoea, acute allergic reactions, connective tissue 
problems (tendon rupture and joint problems), muscle 
pain, confusion, agitation, depression, and prolonged 
QT heartbeat interval [11] [12] [13].  
The present study aims to evaluate the 
efficacy and safety of moxifloxacin in the outpatient 
treatment of moderate bacterial exacerbations in 
COPD patients.  
 
 
Material and Methods 
 
A prospective, observational study (a real life-
study) including 64 COPD patients with moderate 
exacerbation with clinical presentation suggesting 
bacterial origin, 39 males and 25 females, aged 43 to 
77 years. The diagnosis of COPD in all patients was 
established according to the actual GOLD criteria [1]. 
All participants were informed about the study, and 
their written consent was obtained.  
The study was carried out in the period 
August 2017-November 2017 at the Institute for 
Occupational Health of R. Macedonia, Skopje-WHO 
Collaborating Center. The study of the effects of 
various antimicrobial regimens on the clinical course 
of exacerbations of chronic bronchitis and COPD 
carried out by Miravittles et al., [14] was used as a 
model. 
Including criteria was the presence of a 
moderate exacerbation of probably bacterial origin 
which can be managed on an outpatient basis. The 
diagnosis of bacterial exacerbation was defined by the 
patient’s symptoms, using the criteria described by 
Anthonisen et al., [6]. Also, all patients underwent 
clinical examination, spirometry, blood gas 
measurements, ECG, and laboratory analysis. Chest 
X-ray was performed in a part of the patients by 
indications.  
Excluding criteria were mild and severe 
exacerbations, patients with exacerbation type III (one 
cardinal symptom) or type II if increased purulence of 
sputum was not one of the two symptoms, patients 
with asthma, cystic fibrosis, malignancy, pneumonia 
and pulmonary embolism and patients with known 
hypersensitivity to moxifloxacin. 
All study subjects were treated 7 days with 
moxifloxacin 400 mg once daily per os. In about a half 
of the patients enrolled in the study (31/64) 
moxifloxacin was given as an initial empirical 
treatment (Group 1), whereas in the rest of the study 
subjects (33/64) moxifloxacin was given after 
treatment failure with other antibiotic (aminopenicillin 
with clavulanic acid, clarithromycin, or doxycycline) 
(Group 2). The study subjects were advised to 
continue the regular treatment of stable COPD, as 
well as to use short-acting bronchodilators when 
needed. All study subjects had intermediate visits at 3, 
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5 and 7 days at which they were evaluated about the 
duration of symptoms and the side-effects of the drug. 
The course of exacerbation was evaluated as a 
function of the resolution of the symptoms, and the 
treatment was considered to be successful if complete 
resolution of cardinal symptoms or their return to the 
baseline severity was achieved. In addition, 
spirometric parameters, i.e. forced vital capacity 
(FVC), forced expiratory volume in 1 second (FEV1), 
FEV1/FVC ratio, mean expiratory flow at 50% of FVC 
(MEF50), mean expiratory flow at 75% of FVC 
(MEF775), and mean expiratory flow at 25-75% of FVC 
(MEF25-75), at the first visit and at the end of the 
treatment were compared. Relapse rates were 
registered during a 20 days follow-up period in the 
patients with remission of the symptoms.  
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
version 11.0 for Windows. Chi-square test was used 
for testing difference in the prevalence. Comparison of 
the mean time to relief of the symptoms and the mean 
FEV1 values was performed by independent-samples 
t-test. A P-value less than 0.05 was considered as 
statistically significant.  
 
 
Results 
 
The characteristics of the study subjects are 
shown in Table 1. 
Table 1. Characteristics of the study subjects 
Variable Study subjects 
(n = 64) 
Males  
Mean age (years) 
39 (60.9%) 
53.4  9.3 
Mean duration of COPD (years) 
 
COPD severity* 
GOLD 2 (50% ≤ FEV1 < 80% predicted) 
GOLD 3(30% ≤ FEV1 < 50% predicted) 
 
Type of exacerbation** 
Type I  
Type II  
 
Increased dyspnea 
Increased sputum volume 
 Increased sputum purulence 
 
Smoking status*** 
Current smokers  
Pack-years smoked 
Ex-smokers  
Passive smokers  
 
Comorbidities 
Arterial hypertension 
Depression 
Diabetes mellitus type 2 
12.1  5.7 
 
 
34 (53.1%) 
30 (46.9%) 
 
 
35 (54.7%) 
29 (45.3%) 
 
53 (82.8%) 
47 (73.4%) 
64 (100%) 
 
 
18 (28.1%) 
11.7  4.3 
21 (32.8%) 
14 (21.8%) 
 
 
23 (35.9%) 
10 (15.6%) 
7 (10.9%) 
Numerical data are expressed as a mean value with standard deviation; the frequencies 
as a number and percentage of examinees with a certain variable. COPD: chronic 
obstructive pulmonary disease: GOLD: Global Initiative for Chronic Obstructive Lung 
Disease; FEV1: forced expiratory volume in 1 second. * COPD severity was defined 
according to the severity of airflow limitation [1]; ** Type of exacerbation was defined 
according to the Anthonisen et al., [6] classification; *** Classification of smoking status 
was done according to the World Health Organization recommendations [15]. 
 
Moxifloxacin was not discontinued 
prematurely in any patient enrolled in the study. The 
percentage of clinical success (i.e. complete 
resolution of the cardinal symptoms or their return to 
the baseline severity) in all study subjects was 84.3% 
(54/64) being similar in the study subjects of both 
Group 1 (83.9%, i.e. 26/31) and Group 2 (84.8%, i.e. 
28/33) (Figure 1).  
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Figure 1: the Clinical success of the treatment with moxifloxacin 
 
The mean time to complete resolution of the 
cardinal symptoms or their return to the baseline 
severity was 5.2 ± 1.1 days. The mean time to 
complete resolution of the certain cardinal symptoms 
or their return to the baseline severity is given in 
Figure 2. 
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Figure 2: Mean time to complete resolution of the certain cardinal 
symptoms or their return to the baseline severity 
 
Mean values of the measured spirometric 
parameters after the treatment with moxifloxacin were 
significantly higher as compared to their pre-treatment 
mean values (Table 2). 
Table 2: Pre-and post-treatment mean values of the spirometric 
parameters 
Spirometric parameter Pre-treatment 
mean value 
(% pred) 
Post-treatment 
mean value 
(% pred) 
P-value 
FVC 
FEV1 
FEV1/FVC ratio 
69.4 ± 8.7 
50.1 ± 7.4 
0.57 ± 0.05 
74.3 ± 9.1 
54.7 ± 6.7 
0.61 ± 0.03 
0.0023 
0.0003 
0.0000 
MEF50 
MEF75 
MEF 25-75 
43.5 ± 9.7 
34.1 ± 11.3 
62.4 ± 10.8 
49.2 ± 10.2 
38.3 ± 9.4 
68.1 ± 11.2 
0.0015 
0.0239 
0.0040 
% pred: % of predicted value; FVC: forced vital capacity; FEV1: forced expiratory volume in 
1 second; MEF50: mean expiratory flow at 50% of FVC; MEF75: mean expiratory flow at 
75% of FVC; MEF25-75: mean expiratory flow at 25-75% of FVC.  
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The incidence of adverse effects during the 
treatment with moxifloxacin in all study subjects was 
7.8% (5/64), 6.5% in the Group 1 (2/31) and 9.1% in 
the Group 2 (3/33) (Figure 3). Registered side effects 
were mild and self-limited, i.e. there was no serious 
adverse effect that required discontinuation of the 
treatment. Dyspeptic problems (nausea, vomiting, and 
epigastric pain), headache and dizziness were the 
most frequent adverse events. 
9.1
6.5
7.8
0
10
20
30
40
50
60
70
80
90
100
All study subjects Group 1 Group 2
Study subjects
P
er
ce
n
ta
g
e 
(%
)
 
Figure 3: Incidence of adverse effects during the treatment with 
moxifloxacin 
 
Relapse during a 20 days follow-up period 
was registered in 7.4% of the all study subjects with 
complete resolution of the cardinal symptoms or their 
return to the baseline severity (4/54), i.e. in two 
patients from both Group 1 and Group 2 (7.6% and 
7.1%, respectively) (Figure 4). 
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Figure 4: Incidence of relapses after treatment with moxifloxacin 
during 20 days follow-up period  
 
 
Discussion 
 
COPD is one of the leading causes of 
morbidity and mortality worldwide that induces 
substantial and increasing economic and social 
burden. Also, exacerbations are the most frequent 
cause of hospitalisation and death in patients with 
COPD, so their treatment and prevention have great 
importance in the management of the disease. 
In the present study, we assessed the efficacy 
and safety of moxifloxacin in the outpatient treatment 
of moderate COPD exacerbations with clinical 
manifestations indicating bacterial origin. The 
diagnosis of exacerbation was based on the presence 
of clinical symptoms and lung function measurements 
without microbiological evaluation of the sputum. 
According to the actual recommendations, sputum 
analysis should be reserved for patients with frequent 
exacerbations and for chronic purulent sputum in 
whom the presence of more virulent and/or more 
resistant bacteria is likely [3] [9] [16]. Moxifloxacin was 
an initial treatment in about a half of the study 
subjects, whereas in the rest it was given following 
treatment failure with amoxicillin with clavulanic acid, 
clarithromycin, or doxycycline. We found a large 
proportion of active and passive smokers among 
examined subjects that was similar to its prevalence in 
adults documented in our previous studies [17] [18].  
Results of the present study indicated a high 
clinical success rate (84.3%) and time-course of the 
recovery (5.2 days). Similar results were obtained in 
our study on efficacy and tolerability of eight 
antimicrobial regimens in the outpatient treatment of 
exacerbations of COPD performed in 2013. Namely, 
the clinical success rate for moxifloxacin in that study 
was 80.9%, while the mean time for complete 
resolution of the symptoms of exacerbation or their 
return to the baseline severity was 5.7 days [19] [20]. 
Furthermore, results indicating a high efficacy of 
moxifloxacin in the treatment of COPD exacerbations 
were obtained in several other studies. In the meta-
analysis of 11 randomized controlled studies Kai-
Xiong et al. found that moxifloxacin was as clinically 
equivalent and bacteriologically superior to the 
antibiotic regimens routinely used in patients with 
exacerbations of CB and COPD and concluded that 
therapy with moxifloxacin might be a promising and 
safe alternative to empirical treatment for CB and 
COPD exacerbations [21]. Also, in the comparison of 
the efficacy of oral moxifloxacin versus other 
intravenous antibiotics in patients with COPD 
exacerbations requiring urgent admission, Juan Pator 
et al., found that ab initio oral moxifloxacin is an 
effective alternative to other intravenous antibiotics 
(amoxicillin with clavulanic acid, ceftriaxone, or 
levofloxacin) [22].  
In a prospective observational study 
conducted in eight Eastern European countries 
including 2,536 patients older than 35 years with CB 
or COPD exacerbation treated with moxifloxacin for 5, 
7 and 10 days, Chuchalin et al., reported very good or 
good efficacy in 97.7% of the treated patients, 
sufficient in 1.8%, and insufficient in 0.5% [23]. In the 
Moxifloxacin in Acute Exacerbations of Chronic 
Bronchitis Trial (MAESTRAL), Wilson et al., found 
significantly lower clinical failure rates in the patients 
with COPD exacerbations treated with moxifloxacin as 
compared to the patients treated with amoxicillin with 
clavulanic acid [24].  
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There is consistent evidence that the most 
commonly associated side effects of antibiotics used 
in the treatment of COPD exacerbations are 
gastrointestinal and that the risk of Clostridium 
difficile-associated diarrhoea may be increased with 
antibiotic use [25]. In the present study, we found a 
low incidence of mild side effects during the 
moxifloxacin treatment (7.8%) that did not require its 
discontinuation. Similar incidence and severity of the 
adverse effects during moxifloxacin therapy were 
found in our study performed in 2013 (7.1%) [19]. The 
incidence of side effects ranging from 4 to 12% is 
reported in several studies on the safety of 
moxifloxacin during treatment of COPD exacerbations 
[21] [24] [26]. In the study performed by Chuchalin et 
al. reported incidence of serious adverse effects 
during moxifloxacin treatment (atrial fibrillation, acute 
myocardial infarction, diplopia, allergic oedema, 
amnesia, and skin reaction) considered to be drug-
related was 0.15% [23]. 
One of the main goals of treatment of COPD 
exacerbations is to prevent the development of 
subsequent events as exacerbations can cluster in 
time, and once a COPD patients experience an 
exacerbation, they will show increased susceptibility 
to another event [1] [27]. In the present study, the 
incidence of relapses during the follow-up period was 
7.4%. Several studies indicated a low incidence of 
relapses after the treatment of COPD exacerbations 
with moxifloxacin and a prolonged time to the next 
exacerbation [28] [29] [30].  
The present study must be interpreted within 
the context of its limitations. First, the results obtained 
should be viewed with caution, since the study was 
neither blinded nor randomised and, therefore, can be 
a subject to possible selection bias. On the other 
hand, the study design may be its strength, as it is 
documented by other real life-studies. Second, a 
relatively small number of the study subjects could 
have certain implications on the data obtained and its 
interpretation. Third, the short follow-up period could 
also have certain implications on the data obtained 
and its interpretation.  
In conclusion, in a prospective, observational 
study on efficacy and tolerability of moxifloxacin in the 
treatment of moderate exacerbations of COPD in the 
outpatient setting, we found high clinical success rate 
and low incidence of side effects indicating good 
tolerability. Our findings suggest that moxifloxacin can 
be used as a first choice antibiotic in the outpatient 
treatment of moderate bacterial exacerbations of 
COPD.  
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